274 related articles for article (PubMed ID: 34476330)
21. Comparing Clonality Between Components of Combined Hepatocellular Carcinoma and Cholangiocarcinoma by Targeted Sequencing.
Jeon J; Maeng LS; Bae YJ; Lee EJ; Yoon YC; Yoon N
Cancer Genomics Proteomics; 2018; 15(4):291-298. PubMed ID: 29976634
[TBL] [Abstract][Full Text] [Related]
22. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.
Yin X; Zhang BH; Qiu SJ; Ren ZG; Zhou J; Chen XH; Zhou Y; Fan J
Ann Surg Oncol; 2012 Sep; 19(9):2869-76. PubMed ID: 22451237
[TBL] [Abstract][Full Text] [Related]
23. Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival?
Yang J; Huang JY; Chen X; Ling WW; Luo Y; Shi YJ; Liu JB; Lu Q; Lyshchik A
Eur Radiol; 2021 Aug; 31(8):6397-6405. PubMed ID: 33492470
[TBL] [Abstract][Full Text] [Related]
24. Combined hepatocellular-cholangiocarcinoma: An update.
Beaufrère A; Calderaro J; Paradis V
J Hepatol; 2021 May; 74(5):1212-1224. PubMed ID: 33545267
[TBL] [Abstract][Full Text] [Related]
25. Imaging features of combined hepatocellular and cholangiocarcinoma compared with those of hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in a Chinese population.
Wang Y; Yang Q; Li S; Luo R; Mao S; Shen J
Clin Radiol; 2019 May; 74(5):407.e1-407.e10. PubMed ID: 30799097
[TBL] [Abstract][Full Text] [Related]
26. Updates in the diagnosis of combined hepatocellular-cholangiocarcinoma.
Sciarra A; Park YN; Sempoux C
Hum Pathol; 2020 Feb; 96():48-55. PubMed ID: 31931021
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological features and prognosis of combined hepatocellular carcinoma and cholangiocarcinoma after surgery.
Lee SD; Park SJ; Han SS; Kim SH; Kim YK; Lee SA; Ko YH; Hong EK
Hepatobiliary Pancreat Dis Int; 2014 Dec; 13(6):594-601. PubMed ID: 25475861
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Imaging and Clinically Relevant Features of Combined Hepatocellular Carcinoma and Cholangiocarcinoma with Hepatocellular Carcinoma.
Huang X; Li Y; Long L
Med Sci Monit; 2019 Nov; 25():8595-8601. PubMed ID: 31726461
[TBL] [Abstract][Full Text] [Related]
29. Longterm prognosis of combined hepatocellular carcinoma-cholangiocarcinoma following liver transplantation and resection.
Jung DH; Hwang S; Song GW; Ahn CS; Moon DB; Kim KH; Ha TY; Park GC; Hong SM; Kim WJ; Kang WH; Kim SH; Yu ES; Lee SG
Liver Transpl; 2017 Mar; 23(3):330-341. PubMed ID: 28027599
[TBL] [Abstract][Full Text] [Related]
30. Combined Hepatocellular-Cholangiocarcinoma: Changes in the 2019 World Health Organization Histological Classification System and Potential Impact on Imaging-Based Diagnosis.
Kim TH; Kim H; Joo I; Lee JM
Korean J Radiol; 2020 Oct; 21(10):1115-1125. PubMed ID: 32729276
[TBL] [Abstract][Full Text] [Related]
31. Keratin 19-expressing hepatocellular carcinoma and small-duct type intrahepatic cholangiocarcinoma show a similar postoperative clinical course but have distinct genetic features.
Akita M; Ajiki T; Fukumoto T; Itoh T; Zen Y
Histopathology; 2019 Sep; 75(3):385-393. PubMed ID: 31017316
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive analyses of the clinicopathological features and genomic mutations of combined hepatocellular-cholangiocarcinoma.
Ito T; Ishii T; Takeda H; Sumiyoshi S; Tomofuji K; Wakama S; Makino K; Horie H; Kumagai K; Takai A; Uebayashi EY; Ogiso S; Fukumitsu K; Haga H; Seno H; Hatano E
Hepatol Res; 2024 Jan; 54(1):103-115. PubMed ID: 37699724
[TBL] [Abstract][Full Text] [Related]
33. Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: A multicentric retrospective study.
Gigante E; Bouattour M; Bedoya JU; Regnault H; Ziol M; Assenat E; Paradis V; Calderaro J; Ganne-Carrié N; Bouhier-Leporrier K; Amaddeo G; Nault JC
United European Gastroenterol J; 2024 May; 12(4):429-439. PubMed ID: 38059651
[TBL] [Abstract][Full Text] [Related]
34. Combined hepatocellular-cholangiocarcinoma after tetralogy of Fallot repair: a case report and review of literature.
Yugawa K; Kohashi K; Itoh S; Yoshizumi T; Sakamoto I; Tsutsui H; Mori M; Oda Y
Pathol Res Pract; 2020 May; 216(5):152908. PubMed ID: 32143908
[TBL] [Abstract][Full Text] [Related]
35. Cholangiolocellular Carcinoma With "Ductal Plate Malformation" Pattern May Be Characterized by ARID1A Genetic Alterations.
Sasaki M; Sato Y; Nakanuma Y
Am J Surg Pathol; 2019 Mar; 43(3):352-360. PubMed ID: 30520820
[TBL] [Abstract][Full Text] [Related]
36. The diagnostic conundrum and liver transplantation outcome for combined hepatocellular-cholangiocarcinoma.
Panjala C; Senecal DL; Bridges MD; Kim GP; Nakhleh RE; Nguyen JH; Harnois DM
Am J Transplant; 2010 May; 10(5):1263-7. PubMed ID: 20420633
[TBL] [Abstract][Full Text] [Related]
37. Combined hepatocellular-cholangiocarcinoma with angiosarcomatoid change: A case report with immunohistochemical study.
Hakozaki M; Ito S; Fujii T; Kiya Y; Udagawa H; Fukayama M; Fukusato T
Pathol Int; 2019 Feb; 69(2):110-116. PubMed ID: 30672653
[TBL] [Abstract][Full Text] [Related]
38. Activation of the Akt/mammalian target of rapamycin pathway in combined hepatocellular carcinoma and cholangiocarcinoma: significant correlation between p-4E-BP1 expression in cholangiocarcinoma component and prognosis.
Okumura Y; Kohashi K; Tanaka Y; Kato M; Maehara Y; Ogawa Y; Oda Y
Virchows Arch; 2020 Jun; 476(6):881-890. PubMed ID: 31927624
[TBL] [Abstract][Full Text] [Related]
39. Combined hepatocellular carcinoma and cholangiocarcinoma: a case report and review of the literature.
Zhou YM; Yang JM; Wang B; Xu F; Tong Y; Li DQ
Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):656-9. PubMed ID: 18086637
[TBL] [Abstract][Full Text] [Related]
40. Meta-analysis of gene expression profiles identifies differential biomarkers for hepatocellular carcinoma and cholangiocarcinoma.
Likhitrattanapisal S; Tipanee J; Janvilisri T
Tumour Biol; 2016 Sep; 37(9):12755-12766. PubMed ID: 27448818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
